CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse

Csaba M. Banki, Lajos Karmacsi, Garth Bissette, Charles Nemeroff

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Immunoreactive corticotropin-releasing hormone (CRH) and somatostatin (SRIF) were measured in the cerebrospinal fluid (CSF) of 24 female in-patients, suffering from DSM-III-R major depression, both before and after antidepressant treatment. In the total group there were no significant differences between pre- and post-treatment CSF-CRH and SRIF concentrations despite satisfactory clinical improvement in each patient. However, there was a significant post-treatment reduction of the CSF-CRH concentration in the 15 patients who remained depression-free for at least 6 months following treatment, in contrast to the tendency for elevation in those 9 subjects who relapsed within 6 months. CSF-SRIF showed no similar pattern. High, or even increasing, CSF-CRH concentration during antidepressant treatment may indicate lack of normalization of an underlying process in major depression despite symptomatic improvement and predicted early relapse.

Original languageEnglish
Pages (from-to)107-113
Number of pages7
JournalEuropean Neuropsychopharmacology
Volume2
Issue number2
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Corticotropin-Releasing Hormone
Somatostatin
Antidepressive Agents
Cerebrospinal Fluid
Recurrence
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders

Keywords

  • Cerebrospinal fluid
  • Corticotropin-releasing hormone
  • Major depression
  • Relapse
  • Somatostatin

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

CSF corticotropin-releasing hormone and somatostatin in major depression : response to antidepressant treatment and relapse. / Banki, Csaba M.; Karmacsi, Lajos; Bissette, Garth; Nemeroff, Charles.

In: European Neuropsychopharmacology, Vol. 2, No. 2, 01.01.1992, p. 107-113.

Research output: Contribution to journalArticle

@article{151d20528bbf4aebb4a4729a64f4303f,
title = "CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse",
abstract = "Immunoreactive corticotropin-releasing hormone (CRH) and somatostatin (SRIF) were measured in the cerebrospinal fluid (CSF) of 24 female in-patients, suffering from DSM-III-R major depression, both before and after antidepressant treatment. In the total group there were no significant differences between pre- and post-treatment CSF-CRH and SRIF concentrations despite satisfactory clinical improvement in each patient. However, there was a significant post-treatment reduction of the CSF-CRH concentration in the 15 patients who remained depression-free for at least 6 months following treatment, in contrast to the tendency for elevation in those 9 subjects who relapsed within 6 months. CSF-SRIF showed no similar pattern. High, or even increasing, CSF-CRH concentration during antidepressant treatment may indicate lack of normalization of an underlying process in major depression despite symptomatic improvement and predicted early relapse.",
keywords = "Cerebrospinal fluid, Corticotropin-releasing hormone, Major depression, Relapse, Somatostatin",
author = "Banki, {Csaba M.} and Lajos Karmacsi and Garth Bissette and Charles Nemeroff",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0924-977X(92)90019-5",
language = "English",
volume = "2",
pages = "107--113",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - CSF corticotropin-releasing hormone and somatostatin in major depression

T2 - response to antidepressant treatment and relapse

AU - Banki, Csaba M.

AU - Karmacsi, Lajos

AU - Bissette, Garth

AU - Nemeroff, Charles

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Immunoreactive corticotropin-releasing hormone (CRH) and somatostatin (SRIF) were measured in the cerebrospinal fluid (CSF) of 24 female in-patients, suffering from DSM-III-R major depression, both before and after antidepressant treatment. In the total group there were no significant differences between pre- and post-treatment CSF-CRH and SRIF concentrations despite satisfactory clinical improvement in each patient. However, there was a significant post-treatment reduction of the CSF-CRH concentration in the 15 patients who remained depression-free for at least 6 months following treatment, in contrast to the tendency for elevation in those 9 subjects who relapsed within 6 months. CSF-SRIF showed no similar pattern. High, or even increasing, CSF-CRH concentration during antidepressant treatment may indicate lack of normalization of an underlying process in major depression despite symptomatic improvement and predicted early relapse.

AB - Immunoreactive corticotropin-releasing hormone (CRH) and somatostatin (SRIF) were measured in the cerebrospinal fluid (CSF) of 24 female in-patients, suffering from DSM-III-R major depression, both before and after antidepressant treatment. In the total group there were no significant differences between pre- and post-treatment CSF-CRH and SRIF concentrations despite satisfactory clinical improvement in each patient. However, there was a significant post-treatment reduction of the CSF-CRH concentration in the 15 patients who remained depression-free for at least 6 months following treatment, in contrast to the tendency for elevation in those 9 subjects who relapsed within 6 months. CSF-SRIF showed no similar pattern. High, or even increasing, CSF-CRH concentration during antidepressant treatment may indicate lack of normalization of an underlying process in major depression despite symptomatic improvement and predicted early relapse.

KW - Cerebrospinal fluid

KW - Corticotropin-releasing hormone

KW - Major depression

KW - Relapse

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0026875913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026875913&partnerID=8YFLogxK

U2 - 10.1016/0924-977X(92)90019-5

DO - 10.1016/0924-977X(92)90019-5

M3 - Article

C2 - 1352999

AN - SCOPUS:0026875913

VL - 2

SP - 107

EP - 113

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 2

ER -